A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
News
The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for…
The U.S. Food and Drug Administration (FDA) has approved Boruzu, a ready-to-use injectable formulation of bortezomib, for treating adults with multiple myeloma and mantle…
Supporters are gearing up to learn, educate, and fundraise in observance of Blood Cancer Awareness Month, which is held each September to increase awareness…
The U.S. Food and Drug Administration (FDA) has rejected Regeneron Pharmaceuticals’ application for approval of linvoseltamab to treat adults with relapsed or refractory…
Kite Pharma has initiated iMMagine-3, a global Phase 3 clinical trial that’s set to test anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy, against…
Adding Sarclisa (isatuximab) to standard induction therapy for transplant-eligible people with newly diagnosed multiple myeloma extends the time patients live without their disease…
The U.S. Food and Drug Administration (FDA) has approved a new quadruple regimen including Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a first-line approach for adults…
A blood test measuring numbers of lymphocytes, a type of immune cell, may predict how well people with relapsed multiple myeloma will respond to…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment